Single Versus Double Dose Tamsulosin for Patients with Moderate or Severe Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: Prospective Randomized Study
Abstract
Background: As men age, the prevalence of lower urinary tract symptoms (LUTS) linked with benign prostatic hyperplasia (BPH) rises. By the time they are 70 years old, almost 80% of men have been found to have BPH-related LUTS. LUTS, such as incomplete urination, frequency, urgency, nocturia, and reduced urine flow, appear in patients with BPH. Objective: We aimed to evaluate the efficacy and safety of single versus double dose of tamsulosin 0.4 mg for treatments of LUTS/BPH. Patients and methods: A double-blinded randomized controlled trial was conducted in the Outpatients Clinics for BPH-associated moderate and severe LUTS. Patients were randomized to receive single dose tamsulosin 0.4 mg capsule (1st group n = 33), and double dose tamsulosin 0.4 mg capsule (2nd group n= 32). The primary endpoints were the changes in International Prostate Symptom Score (IPSS), Uroflowmetry and PVR urine volume before starting the study, after one month and after 3 months of the treatment. Results: Total IPSS was more decreased (improved) in double dose tamsulosin 0.4 mg group than single dose tamsulosin 0.4 mg group, with P-value = 0.005 at one month follow up and 0.007 at three months follow up, which was statistically significant. However, dizziness was more frequent in double dose tamsulosin 0.4 mg group than in single dose tamsulosin 0.4 mg group (with P = 0.03 at one month follow up and P= 0.01 at three months follow up), which was statistically significant. Conclusion: Tamsulosin…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 33 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.